Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 117 of 6351
-
Can a platform trial match the right drug combo to each tumor?
Disease control Recruiting nowPRE-ISPY Phase I/II (I-SPY-P1) is an open-label, multisite platform study with multiple ongoing drug regimen arms added by protocol amendment which is designed to evaluate single agents or combinations in locally advanced, incurable, or metastatic solid tumors and/or oligometasta…
Phase 1/2 • Sponsor: QuantumLeap Healthcare Collaborative • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Gene therapy aims to halt rare childhood paralysis disorder
Disease control Recruiting nowMELPIDA is proposed for the treatment of subjects with SPG50 and targets neuronal cells to deliver a fully functional human AP4M1 cDNA copy via intrathecal injection to counter the associated neuronal loss. Outcomes will evaluate the safety and tolerability of a single dose of ME…
Phase 1/2 • Sponsor: Elpida Therapeutics SPC • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Magic mushroom compound takes on depression in major trial
Symptom relief OngoingEfficacy, Safety, and Tolerability of two administrations of COMP360 in participants with treatment-resistant depression (TRD)
Phase 3 • Sponsor: COMPASS Pathways • Aim: Symptom relief
Last updated Aug 12, 2026 00:00 UTC
-
Triple therapy aims to boost Cancer-Free survival after surgery for HER2-Positive stomach cancer
Disease control CompletedThe study is an open-label, single arm, multicenter phase II trial investigating the clinical activity of a perioperative therapy consisting of a combination of pembrolizumab, trastuzumab and FLOT, followed by pembrolizumab plus trastuzumab alone for a maximum systemic treatment …
Phase 2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a single injection save sight in a rare retinal disease?
Cure OngoingEvaluate the safety and tolerability of NGGT001 subretinal injection for the treatment of crystalline retinal degeneration (BCD)
Early phase 1 • Sponsor: Xiamen Ophthalmology Center Affiliated to Xiamen University • Aim: Cure
Last updated Aug 19, 2026 00:00 UTC
-
Engineered immune cells take on Hard-to-Treat blood cancers
Disease control Recruiting nowThis is a phase l, single arm, prospective open, dose-escalation study in patients with relapsed or refractory CD19-positive B cell malignancies (ALL, NHL, CLL). The trial will include adult and pediatric patients. There will be three individual cohorts, defined by disease biolog…
Phase 1 • Sponsor: Nelson Hamerschlak • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New combo therapy aims to outperform standard immunotherapy for lung cancer
Disease control OngoingThe purpose of this study is to compare pembrolizumab (MK-3475) in combination with sacituzumab govitecan with pembrolizumab alone with respect to progression-free survival (PFS) and overall survival (OS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) a…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Can a simple eye-tracking test spot autism in babies before their first birthday?
Diagnosis Recruiting nowThe goal of this project is to measure the clinical utility of an objective and quantitative eye-tracking assay collected on a standalone, mobile investigational device to accurately screen 9-month-old infants for autism spectrum disorder and other actionable delays.
Sponsor: Emory University • Aim: Diagnosis
Last updated Jun 27, 2026 13:02 UTC
-
New combo shot CagriSema shows promise for weight loss in type 2 diabetes
Disease control CompletedThis study will look at how well the new medicine CagriSema helps people living with excess body weight and type 2 diabetes losing weight. Participants will either get CagriSema or a dummy medicine. Which treatment they get is decided by chance. The study will last for about 1½ …
Phase 3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New shot could cut bleeding episodes in severe hemophilia
Disease control OngoingThis is a multicenter, multinational, open-label, one-way cross-over, Phase 3, single-arm study for treatment of hemophilia. The purpose of this study is to measure the frequency of treated bleeding episodes with fitusiran in male adult and adolescent (≥12 years old) participant…
Phase 3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Stenting unstable plaques: a new way to prevent second heart attacks?
Disease control OngoingThe study aims to compare a preventive percutaneous coronary intervention (PCI) plus optimal medical treatment (OMT) strategy vs. OMT for treatment of non-functionally significant non-culprit lesions presenting with optical coherence tomography (OCT) findings indicative of vulner…
Sponsor: Fundación EPIC • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Bone marrow transplant or drugs? landmark trial for rare blood disease
Disease control OngoingSevere Aplastic Anemia (SAA) is a rare condition in which the body stops producing enough new blood cells. SAA can be cured with immune suppressive therapy or a bone marrow transplant. Regular treatment for patients with aplastic anemia who have a matched sibling (brother or sist…
Phase 3 • Sponsor: Boston Children's Hospital • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Dementia prevention breakthrough? metformin and lifestyle combo tested in major trial
Prevention OngoingDementia is the main cause of disability in older adults, currently affecting about 50 million people world-wide with this number estimated to triple in the next 30 years. In MET-FINGER, we aim to understand whether the FINGER 2.0 multidomain intervention, combining healthy lifes…
Phase 2 • Sponsor: Imperial College London • Aim: Prevention
Last updated Jul 12, 2026 00:00 UTC
-
Magic mushroom compound takes on tough depression in major trial
Symptom relief CompletedEfficacy, Safety, and Tolerability of a single administration of COMP360 in participants with treatment-resistant depression (TRD)
Phase 3 • Sponsor: COMPASS Pathways • Aim: Symptom relief
Last updated Aug 12, 2026 00:00 UTC
-
Can mRNA technology outsmart shingles? a new vaccine trial aims to find out
Vaccine Stopped earlyThe purpose of this first-in-human study is to evaluate the safety and immunogenicity of mRNA-1468.
Phase 1 • Sponsor: ModernaTX, Inc. • Aim: Vaccine
Last updated Aug 07, 2026 00:00 UTC
-
Gene-Edited stem cells may let doctors use stronger chemo against brain cancer
Disease control Recruiting nowThis phase II trial studies the effect of P140K MGMT hematopoietic stem cells, O6-benzylguanine, temozolomide, and carmustine in treating participants with supratentorial glioblastoma or gliosarcoma who have recently had surgery to remove most or all of the brain tumor (resected)…
Phase 2 • Sponsor: Leland Metheny • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New hope for High-Risk melanoma: combo therapy aims to prevent recurrence
Disease control Stopped earlyThe primary purpose of this study is to compare pembrolizumab/vibostolimab to pembrolizumab with respect to recurrence-free survival (RFS). The primary hypothesis is that pembrolizumab/vibostolimab is superior to pembrolizumab with respect to RFS as assessed by the investigator i…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
New immunotherapy duo aims to stop melanoma recurrence
Disease control OngoingThis study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called cemiplimab (each individually called a "study drug" or called "study drugs" when combined) compared with an approved medication called pem…
Phase 3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Can a gas added to Heart-Lung machines shield Newborns' kidneys?
Prevention Recruiting nowAcute kidney injury (AKI) following cardiac surgery for congenital heart defects (CHD) in children affects up to 60% of high risk-patients and is a major cause of both short- and long-term morbidity and mortality. Despite effort, to date, no successful therapeutic agent has gaine…
Phase 3 • Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Prevention
Last updated Aug 07, 2026 00:00 UTC
-
New Three-Drug cocktail shows promise in Hard-to-Treat myeloma
Disease control OngoingThe purpose of the study is to compare Mezigdomide (CC-92480/BMS-986348) with carfilzomib and dexamethasone (MeziKD) against carfilzomib and dexamethasone (Kd) in the treatment of RRMM: SUCCESSOR-2.
Phase 3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC